World Vaginal Atrophy (Atrophic Vaginitis) API Insights Report 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Vaginal Atrophy (Atrophic Vaginitis) - API Insights - 2017" drug pipelines to their offering.

Vaginal Atrophy (Atrophic Vaginitis) - API Insights, 2017 report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Vaginal Atrophy (Atrophic Vaginitis). It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales data till 2016.

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.

India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

Key Topics Covered:

  1. Indication Overview
  2. Marketed Drugs Assessment
  3. Marketed Details of Drugs by Application Type
  4. Marketed Details of Drugs (NDA) by Marketing Status
  5. Marketed Details of Drugs by Patent Expiration Timeline
  6. The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
  7. The API Manufacturers by the United States Drug Master File (US DMF) Status
  8. The API Manufacturers by the US DMF Status (Drug Specific)
  9. Drugs Market Data and Sales Figures (2012-2016)
  10. Marketed Drugs Information
  11. Drugs Description
  12. Global Active Pharmaceutical Manufacturers
  13. Approval Status
  14. Patent and Exclusivity Details
  15. Company Overview
  16. Discontinued Drugs Information

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/c7dnvf/vaginal_atrophy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Sexual and Reproductive Health Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Women's Health, Sexual and Reproductive Health Drugs